Abivax SA
ABVX71.280USD
-0.665-0.92%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Abivax SA Unternehmen
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Unternehmensinformationen
BörsenkürzelABVX
Name des UnternehmensAbivax SA
IPO-datumJun 26, 2015
CEOMr. Marc De Garidel
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse7-11 Boulevard Haussmann
StadtPARIS
BörseEuronext Paris
LandFrance
Postleitzahl75009
Telefon33153830963
Websitehttps://www.abivax.com/
BörsenkürzelABVX
IPO-datumJun 26, 2015
CEOMr. Marc De Garidel
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Ana Sharma
Ms. Ana Sharma
Vice President - Global Head of Quality
Vice President - Global Head of Quality
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Patrick Malloy
Mr. Patrick Malloy
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael Ferguson
Mr. Michael Ferguson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Board Secretary
Chief Financial Officer, Board Secretary
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Dr. Fabio Cataldi, M.D.
Dr. Fabio Cataldi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, May 18
Aktualisiert: Sun, May 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Aktionäre
Aktionäre
Anteil
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.86%
Adar1 Capital Management LLC
3.00%
Cormorant Asset Management, LP
2.90%
Great Point Partners, LLC
2.23%
Other
78.78%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
23.84%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
3.77%
Venture Capital
2.49%
Research Firm
2.19%
Other
56.74%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
74
31.84M
43.27%
-317.18K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
TCG Crossover Management, LLC
6.06M
9.55%
--
--
Mar 31, 2025
Deep Track Capital LP
3.58M
5.64%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
2.21M
3.48%
+696.63K
+46.03%
Mar 31, 2025
Cormorant Asset Management, LP
2.13M
3.36%
--
--
Mar 31, 2025
Great Point Partners, LLC
1.64M
2.58%
-10.41K
-0.63%
Mar 31, 2025
Nantahala Capital Management, LLC
1.48M
2.34%
+46.95K
+3.27%
Mar 31, 2025
Citadel Advisors LLC
1.37M
2.17%
+518.18K
+60.56%
Mar 31, 2025
Franklin Advisers, Inc.
1.37M
2.16%
-95.01K
-6.48%
Mar 31, 2025
VR Adviser, LLC
1.35M
2.12%
--
--
Mar 31, 2025
Caligan Partners, LP
1.27M
2%
+516.95K
+68.73%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Innovator IBD Breakout Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
